story of the week
Addition of Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Newly Diagnosed Transplantation-Eligible Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Lancet Haematol 2022 Nov 01;9(11)e810-e821, H Goldschmidt, EK Mai, U Bertsch, R Fenk, E Nievergall, D Tichy, B Besemer, J Dürig, R Schroers, I von Metzler, M Hänel, C Mann, AM Asemissen, B Heilmeier, N Weinhold, S Huhn, K Kriegsmann, SP Luntz, TAW Holderried, K Trautmann-Grill, D Gezer, M Klaiber-Hakimi, M Müller, C Khandanpour, W Knauf, C Scheid, M Munder, T Geer, H Riesenberg, J Thomalla, M Hoffmann, MS Raab, HJ Salwender, KC WeiselFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.